Cellular Immunology, Год журнала: 2025, Номер unknown, С. 104986 - 104986
Опубликована: Июнь 1, 2025
Язык: Английский
Journal of Liposome Research, Год журнала: 2025, Номер unknown, С. 1 - 11
Опубликована: Апрель 25, 2025
Platelets, long recognized for their role in hemostasis and thrombosis, have emerged as key players a wide array of physiological pathological processes through the release platelet-derived extracellular vesicles (PEVs). These nanoscale vesicles, rich bioactive molecules such proteins, lipids, nucleic acids, facilitate intercellular communication influence ranging from angiogenesis inflammation to immune modulation tissue repair. PEVs, most abundant circulation, display procoagulant activity 50-100 times greater than activated platelets, underscoring pivotal thrombosis. Recent research has unveiled dual health disease, highlighting potential diagnostic biomarkers therapeutic vehicles. PEVs are implicated cancer progression, autoimmune diseases, infectious where they modulate tumor microenvironments, responses, inflammatory pathways. Moreover, ability deliver agents with high specificity biocompatibility positions them promising tools regenerative medicine, drug delivery, targeted therapies. This review comprehensively explores PEV biogenesis, cargo composition, multifaceted roles well broader implications disease. It also markers innovative strategies, offering insights into application treating thrombotic disorders, cancer, diseases. Despite significant advancements, challenges remain standardizing isolation protocols translating preclinical findings clinical applications. Unlocking full promises revolutionize diagnostics therapeutics, paving way novel approaches managing complex
Язык: Английский
Процитировано
4
Clinical and Applied Thrombosis/Hemostasis, Год журнала: 2025, Номер 31
Опубликована: Апрель 1, 2025
Recurrent spontaneous abortion (RSA) is a multifactorial condition influenced by genetic, hormonal, immunological, and anatomical factors. Thrombophilia, characterized heightened propensity for blood clotting, significant contributor to RSA. This review examines the mechanisms connecting thrombosis RSA, focusing on hypercoagulable states, placental thrombosis, inflammation, endothelial dysfunction. Genetic acquired thrombophilic factors, such as factor V Leiden mutation, prothrombin gene protein C S deficiencies, antithrombin III deficiency, antiphospholipid syndrome, hyperhomocysteinemia, are discussed in detail. The diagnosis of thrombophilia RSA entails comprehensive clinical evaluation, including assessment physical examination, medical history laboratory investigations, although there still debate over need universal screening. Therapeutic strategies, anticoagulant antiplatelet therapies, well lifestyle modifications, tailored individual risk factors disease severity. Although therapy demonstrates potential lowering miscarriage, additional research necessary refine treatment protocols assess long-term outcomes. highlights nuanced approach managing thrombophilia-associated balancing diagnostic precision with therapeutic efficacy improve reproductive
Язык: Английский
Процитировано
1
Medical Oncology, Год журнала: 2025, Номер 42(6)
Опубликована: Май 6, 2025
Язык: Английский
Процитировано
0
Biomarker Research, Год журнала: 2025, Номер 13(1)
Опубликована: Май 13, 2025
Язык: Английский
Процитировано
0
Molecular Biology Reports, Год журнала: 2025, Номер 52(1)
Опубликована: Май 16, 2025
Язык: Английский
Процитировано
0
Clinical and Experimental Medicine, Год журнала: 2025, Номер 25(1)
Опубликована: Май 17, 2025
Leukemia, a group of blood cancers, presents significant global health challenge. Despite advancements in conventional therapies like chemotherapy and immunotherapy, the need for more effective less toxic treatments remains. Nanotechnology offers promising avenue targeted drug delivery immune modulation fight against leukemia. Through utilization nanomaterials' special qualities, their small size, large surface area, capacity to transport variety payloads, scientists are creating novel ways get around drawbacks treatments. These strategies include delivery, cell activation, overcoming resistance. However, challenges remain translating these nanotechnological approaches into clinical applications. Addressing issues such as toxicity, biodistribution, regulatory hurdles is crucial successful development nanomedicine In conclusion, nanotechnology future treatment Continued research essential unlock full potential nanomaterials improve patient outcomes. The nanotechnology-based effectiveness leukemia explored this review. We go over function different delivering therapeutic agents cells, liposomes, polymeric nanoparticles, inorganic anoparticles. also investigate engineering influence system promote anti-tumor reactions.
Язык: Английский
Процитировано
0
Clinical and Experimental Medicine, Год журнала: 2025, Номер 25(1)
Опубликована: Май 30, 2025
Aptamers, which are intricate synthetic molecules composed of single-stranded DNA and RNA, have recently emerged as groundbreaking instruments in the complex multifaceted realms diagnosing treating diverse challenging cancers, particularly leukemia, a type blood cancer characterized by overproduction abnormal white cells. These innovative chemical antibodies, celebrated for their remarkable cost-effectiveness, unparalleled sensitivity, exceptional precision, provide promising beacon hope arena oncology, field that continuously seeks novel approaches to combat various malignancies. Aptamers fundamentally transforming landscape personalized medicine adeptly specifically targeting aberrantly expressed biomarkers, effectively modulating critical signaling pathways, significantly enhancing efficacy drug delivery systems, thereby optimizing therapeutic outcomes patients. This comprehensive review meticulously highlights recent advancements aptamer-based technologies, showcasing immense potential refine prognostic models, enhance interventions guided presence minimal residual disease, broaden options available patients suffering from high-risk or relapsed forms leukemia. Nevertheless, conjunction with applications, this study also delves into an exploration myriad challenges obstacles may impede realization full clinical healthcare setting.
Язык: Английский
Процитировано
0
Medical Oncology, Год журнала: 2025, Номер 42(7)
Опубликована: Июнь 2, 2025
Язык: Английский
Процитировано
0
Cellular Immunology, Год журнала: 2025, Номер unknown, С. 104986 - 104986
Опубликована: Июнь 1, 2025
Язык: Английский
Процитировано
0